Public Employees Retirement System of Ohio Raises Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Public Employees Retirement System of Ohio boosted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 102.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,756 shares of the company's stock after purchasing an additional 51,876 shares during the quarter. Public Employees Retirement System of Ohio owned 0.13% of Travere Therapeutics worth $1,790,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Entropy Technologies LP bought a new position in Travere Therapeutics in the 4th quarter worth approximately $214,000. US Bancorp DE boosted its holdings in Travere Therapeutics by 323.4% during the fourth quarter. US Bancorp DE now owns 31,795 shares of the company's stock worth $554,000 after buying an additional 24,286 shares during the last quarter. Northern Trust Corp grew its position in shares of Travere Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 754,395 shares of the company's stock worth $13,142,000 after buying an additional 76,358 shares during the period. Swiss National Bank increased its stake in shares of Travere Therapeutics by 12.8% in the 4th quarter. Swiss National Bank now owns 151,900 shares of the company's stock valued at $2,646,000 after acquiring an additional 17,200 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Travere Therapeutics in the 4th quarter valued at approximately $14,222,000.

Travere Therapeutics Stock Down 1.7%

Shares of NASDAQ:TVTX traded down $0.25 during trading on Thursday, reaching $14.97. 136,129 shares of the stock traded hands, compared to its average volume of 1,583,321. The stock has a market cap of $1.33 billion, a P/E ratio of -3.65 and a beta of 0.75. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The stock has a 50-day moving average of $17.08 and a two-hundred day moving average of $18.69. Travere Therapeutics, Inc. has a 52-week low of $6.80 and a 52-week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.08. The firm had revenue of $81.73 million for the quarter, compared to analysts' expectations of $77.44 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business's quarterly revenue was up 83.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.76) EPS. As a group, sell-side analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent analyst reports. Guggenheim reiterated a "buy" rating and set a $47.00 target price on shares of Travere Therapeutics in a report on Monday, April 14th. JPMorgan Chase & Co. upped their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a report on Wednesday, April 23rd. Bank of America lifted their target price on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Finally, Wedbush restated an "outperform" rating and issued a $30.00 target price on shares of Travere Therapeutics in a research report on Friday, May 16th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.79.

Insider Buying and Selling

In other Travere Therapeutics news, insider Peter Heerma sold 1,771 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,279.55. Following the sale, the insider now owns 128,215 shares of the company's stock, valued at approximately $2,698,925.75. The trade was a 1.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Eric M. Dube sold 18,924 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the transaction, the chief executive officer now directly owns 419,173 shares in the company, valued at approximately $8,823,591.65. The trade was a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,527 shares of company stock valued at $473,814 in the last 90 days. Company insiders own 4.06% of the company's stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.